ESSA Pharma (EPIX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

EPIX ESSA Pharma

Watchlist

1.600
0.0000.00%

Close Dec 20 16:00 ET

1.610
+0.010+0.63%

Post 17:54 ET

71.02MMarket Cap-2.50P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?
Yahoo FinanceDec 21 07:59 ET
ESSA Pharma's Cash Management: A Potential Risk to Shareholder Value and Market Stability
TipRanksDec 18 01:00 ET
ESSA Pharma Inc. Reports Strategic Shift Amid Losses
TipRanksDec 17 22:51 ET
ESSA Pharma: Fiscal Q4 Earnings Snapshot
Yahoo FinanceDec 17 07:17 ET
ESSA Pharma Q4 2024 GAAP EPS $(0.14) Beats $(0.21) Estimate, Cash Balance Of $103.71M
BenzingaDec 17 07:12 ET
ESSA Pharma | 8-K: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
SECDec 17 07:08 ET · Announcements

Comments

Joejoejoe0

Nov 11 10:25

$ESSA Pharma (EPIX.US)$ Would not recommend this stock as their pipelines are all around the therapeutic strategies of masofaniten and its combinations which was not that successful in a recent Phase II trail.

Clintzilla

Nov 4 10:02

$ESSA Pharma (EPIX.US)$ might wanna read the pipeline

Stock_Drift

Nov 4 04:29

Pre Market Ticks. 11/4_5:28am

$Verona Pharma (VRNA.US)$ $Safe & Green Development (SGD.US)$ $Globalstar (GSAT.US)$ $SRM Entertainment (SRM.US)$ $Silo Pharma (SILO.US)$ $ESSA Pharma (EPIX.US)$ $SAG Holdings (SAG.US)$ $Tenaya Therapeutics (TNYA.US)$ $Air Transport Services (ATSG.US)$ $Hanryu Holdings (HRYU.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $Singular Genomics (OMIC.US)$ $Nuwellis (NUWE.US)$ $Vast Renewables (VSTE.US)$
📊⚡️📊

WeiTheSaint469

Nov 1 11:51

1.55 but little skeptical about this one

$ESSA Pharma (EPIX.US)$

Jaguar8

Oct 31 19:59

NEWS

$ESSA Pharma (EPIX.US)$
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma announced the termination of its Phase 2 clinical trial evaluating masofaniten combined with enzalutamide in metastatic castration-resistant prostate cancer patients. The decision came after a futility analysis showed the enzalutamide control arm performing better than historical controls and s...

Heat List

Overall

No Data